On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.
Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.
The detection, diagnosis, and treatment of HIV has evolved rapidly. This review summarizes the past, present, and future of antiretrovirals for the treatment and prevention of HIV.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.